PROJECT SUIVIMARY Some form of myelosuppression is necessary for effective and durable engraftment of transplanted genetically corrected autologous stem cells. Milder conditioning protocols which support efficient engraftment but do not subject patients to undue toxicity and risks are highly desirable, but these have not been tested in large animals or humans as yet. In this project we propose too investigate two such innovative conditioning regimens in murine and primate preclinical models. The proposed experiments test the hypothesis that low dose irradiation in combination with either Ab-mediated impairment of stem cell function or with the use of stem cell mobilizing agents will facilitate the engraftment of genetically corrected stem cells. Thus, low dose irradiation will be combined in Specific Aim 1 with anti-human c-kit treatment to reduce the stem/cell progenitor pool and in Specific Aim 2 with a mobilizing agent for displacement of stem/progenitor cells. Ancillary preliminary experiments using similar regimens will be conducted in mice to provide guidance and mechanistic clues. Since not only recipient conditioning is necessary for enhanced engraftment, innovative treatments of donor cells are also important. We will address this issue in Specific Aim 3. To enhance engraftment, in this Specific Aim we exploit short term treatment of in vitro incubated cells of murine or human origin with dmPGE2 and their transplantation in an immunodeticient host (NOD/SCID). Comparison of the behavior of murine vs. human cells treated ex wVo with dmPGE2 will be done in the same immunodeficient recipient model allowing also the approach of mechanistic issues. We believe that results from these experiments will have important clinical implications in transplantation outcomes in humans using autologous gene corrected cells.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL053750-19
Application #
8463854
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
19
Fiscal Year
2013
Total Cost
$66,674
Indirect Cost
$23,769
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Li, Li B; Ma, Chao; Awong, Geneve et al. (2016) Silent IL2RG Gene Editing in Human Pluripotent Stem Cells. Mol Ther 24:582-91
Constantinou, Varnavas C; Bouinta, Asimina; Karponi, Garyfalia et al. (2016) Poor stem cell harvest may not always be related to poor mobilization: lessons gained from a mobilization study in patients with β-thalassemia major. Transfusion :
Psatha, Nikoletta; Karponi, Garyfalia; Yannaki, Evangelia (2016) Optimizing autologous cell grafts to improve stem cell gene therapy. Exp Hematol 44:528-39
Vierstra, Jeff; Reik, Andreas; Chang, Kai-Hsin et al. (2015) Functional footprinting of regulatory DNA. Nat Methods 12:927-30
Liu, Mingdong; Maurano, Matthew T; Wang, Hao et al. (2015) Genomic discovery of potent chromatin insulators for human gene therapy. Nat Biotechnol 33:198-203
Qi, Heyuan; Liu, Mingdong; Emery, David W et al. (2015) Functional validation of a constitutive autonomous silencer element. PLoS One 10:e0124588
Karponi, Garyfalia; Psatha, Nikoletta; Lederer, Carsten Werner et al. (2015) Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy. Blood 126:616-9
Polak, Paz; Karlić, Rosa; Koren, Amnon et al. (2015) Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature 518:360-4
Deyle, David R; Hansen, R Scott; Cornea, Anda M et al. (2014) A genome-wide map of adeno-associated virus-mediated human gene targeting. Nat Struct Mol Biol 21:969-75
Boulad, Farid; Wang, Xiuyan; Qu, Jinrong et al. (2014) Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood 123:1483-6

Showing the most recent 10 out of 160 publications